The newly identified disorder has been termed VITT-like monoclonal gammopathy of thrombotic significance (MGTS). "Our study highlights the importance of recognizing and diagnosing this new blood ...

The U.S. Food and Drug Administration (FDA) has announced the approval of Qfitlia (fitusiran), a treatment designed to ...

Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on safety ...

with their burden often extending to longer-term complications such as event recurrence and post-thrombotic syndrome (PTS). Few data exist on the overall economic burden of DVT and PE and their ...

Additional interests include autoimmune diseases, both autologous and allogeneic bone marrow and peripheral stem cell transplantation, as well as thrombotic and bleeding disorders. SLU’s hemostasis ...

About 30% of people hospitalized due to acquired hemophilia have a bleeding event, while 17% have a blood clot-related ...